Tag Archives: s. 112

Amgen v. Sanofi – How Wands Factors make Biotech Claims “Magically” Disappear

While this recent Fed. Cir. decision – Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir., Feb. 11, 2021) seems predictable, given the fate of antibody claims that recite the target and the function of antibody binding thereto, there are … Continue reading

Posted in Enablement | Tagged , , | Leave a comment

American Axle & Manufacturing v. Neapco Holdings–Part II

In my first post on American Axle’s Petition for cert., I focused on the substantive arguments of the parties. Almost as interesting is Part 5 of the Petition, in which AA argues that this is a good case for the … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

American Axle Petitions for Cert.

You may have noticed that I haven’t been posting since November. I feel like IP law has hunkered down and I find spats over jurisdiction and even the appeal urging the S. Ct. to validate IPR judgeships to be less … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

AAM v. Neapco – Part IV – Petition for Rehearing En Banc Denied – “Bad Vibrations”

This post will briefly discuss the Fed. Cir.’s denial of rehearing en banc – which  left the modified panel opinion stand. The lengthy panel opinion has been the subject of my last three posts, and you should read them before … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment